Journal of Vaccines & Vaccination

Pentavalent vaccine

10^th Euro Global Summit and Expo on Vaccines & Vaccination

June 16-18, 2016 Rome, Italy

Sourabh Sobti

Clinton Health Access Initiative, USA

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

Pentavalent vaccine administered in a 3-dose schedule at 6, 10 and 14 weeks is a key vaccine protecting newborns against Diphtheria, Pertussis, Tetanus, Hepatitis-B and Haemophilus influenzae and is part of Expanded Program of Immunization (EPI) schedule in more than 100 countries globally. While developing countries use DTwP, developed and middle income countries prefer DTaP vaccine which has reduced side effects. Pentavalent vaccine remains a lucrative market with Pentacel and Pediatrix cumulatively registering revenues of $2.9 B in 2014. Gavi support for pentavalent vaccine introduction has now resulted in all Gavi 73 countries introducing pentavalent in their EPI schedule. The talk will feature on pentavalent supply and demand landscape and how entry of multiple developing country vaccine manufacturers and predictabilty of future demand has resulted in significant price reductions year on year for (DTwP-Hep-Hib) pentavalent vaccine.

Biography :

Email: ssobti@clintonhealthaccess.org